Locus Cell Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 10, 2023 at 04:01 am IST
Share
Locus Cell Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was TWD 11.78 million compared to TWD 6.36 million a year ago. Basic loss per share from continuing operations was TWD 0.06 compared to TWD 0.03 a year ago. Diluted loss per share from continuing operations was TWD 0.06 compared to TWD 0.03 a year ago.
For the nine months, net loss was TWD 51.41 million compared to TWD 27.88 million a year ago. Basic loss per share from continuing operations was TWD 0.26 compared to TWD 0.14 a year ago. Diluted loss per share from continuing operations was TWD 0.26 compared to TWD 0.14 a year ago.
Locus Cell Co Ltd is a Taiwan-based company mainly engaged in the biotechnology and pharmaceutical business. The Company is currently expected to provide cell therapy contract manufacturing organization (CDMO) production and development services using a pilot Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) good manufacturing practices (GMP) facility, with related technologies for cell therapy products (expected to include tissue engineering related products, CAR-T, iPSCs, MSC and other cell therapy applications), process development and process scale-up, analytical method development and validation, clinical GMP manufacturing process for clinical trials, and stability testing.
LOCUS CELL CO., LTD. 
